RxDoctor Payments Data

Natasha Chokshi

Optometrist · Prospect, CTNPI 1518316462

Payments from drug & device makers

$1,260in general payments, 2019–2025

Across 38 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$397
  • Alcon$327
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$276
  • Sun Pharmaceutical Industries Inc.$96
  • AbbVie$77
  • Oyster Point Pharma, Inc.$30
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$1,24399%
  • Entertainment$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,260 in reported general payments places this provider in the 55th percentile of 574 optometrist providers in Connecticut.

See all optometrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$92,830
Medicare patients
467
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate32$20,931
RestasisCyclosporine29$20,653
MieboPerfluorohexyloctane/Pf17$15,100
LumiganBimatoprost26$13,660
VyzultaLatanoprostene Bunod21$8,530
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,158
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha94$967
Latanoprost85$829
Prednisolone Acetate22$627
ErythromycinErythromycin Base12$81
Timolol Maleate19$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$77$34,31355 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$397$23,63038 claims
Oyster Point Pharma, Inc.Tyrvaya$30$20,93132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 574 optometrist providers in Connecticut.

Other optometrist in Prospect

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →